Atrium Therapeutics, Inc. (RNA) has a consensus analyst rating of Hold, based on 16 analysts covering the stock. Of those, 7 recommend buying, 9 recommend holding, and 0 recommend selling.
The analyst consensus price target for RNA is $54.50, representing a +288.7% upside from the current price of $14.02. Price targets range from a low of $50.00 to a high of $59.00.
